Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 2Phase 1 2Phase NA 1Phase 2 1

Status

Withdrawn 2Completed 2Unknown 1Terminated 1Suspended 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Pain Related to Cancer 1Neoplasms 1

Interventions

Cyclophosphamide 297Cisplatin 297Paclitaxel 258Radiotherapy 253Fluorouracil 234Carboplatin 234Docetaxel 231Doxorubicin 212Dexamethasone 164Gemcitabine 155Vincristine 143Etoposide 133Leucovorin 132Capecitabine 129Bevacizumab 129Prednisone 124Rituximab 118Methotrexate 117Cytarabine 108Filgrastim 99Trastuzumab 98Oxaliplatin 96pembrolizumab 81Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Nivolumab 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Completed × Methadone × Clear all
NCT01793480 2024-10-31

EQUIMETH2

RECORDATI GROUP

Phase 3 Completed
146 enrolled

Pain Related to Cancer

NCT00184496 2014-02-28

Switching From Morphine to Methadone. A Clinical, Pharmacological and Pharmacogenetic Study

Norwegian University of Science and Technology

Phase 3 Completed
42 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡